The emerging pathogen Candida auris: Growth phenotype, virulence factors, activity of antifungals, and effect of SCY-078, a novel glucan synthesis inhibitor, on growth morphology and biofilm formation

Antimicrobial Agents and Chemotherapy

Volumn 61, Issue 5, 2017, Pages

  Larkin, Emily ^a   Hager, Christopher ^a   Chandra, Jyotsna ^a   Mukherjee, Pranab K ^a   Retuerto, Mauricio ^a   Salem, Iman ^a   Long, Lisa ^a   Isham, Nancy ^a   Kovanda, Laura ^b   Borroto Esoda, Katyna ^c   Wring, Steve ^c   Angulo, David ^c   Ghannoum, Mahmoud ^a  

^a UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

^b ASTELLAS PHARMA GLOBAL DEVELOPMENT   (United States)

^c Scynexis   (United States)

Author keywords

Biofilm; Candida auris; SCY 078; Virulence

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; BETA 1,3 GLUCAN; CASPOFUNGIN; FLUCONAZOLE; GLUCAN SYNTHESIS INHIBITOR; MICAFUNGIN; PHOSPHOLIPASE; PROTEINASE; SCY 078; UNCLASSIFIED DRUG; VIRULENCE FACTOR; GLUCAN; GLYCOSIDE; MK-3118; PEPTIDE HYDROLASE; TRITERPENE;

AGED; ANTIFUNGAL ACTIVITY; ANTIFUNGAL RESISTANCE; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA; CANDIDA ALBICANS; CANDIDA AURIS; CELL DIVISION; CONTROLLED STUDY; DRUG POTENCY; FUNGAL CELL; FUNGAL METABOLISM; FUNGAL SPORE GERMINATION; FUNGAL STRAIN; FUNGAL STRUCTURES; FUNGUS GROWTH; FUNGUS ISOLATION; HUMAN; MALE; MIC50; MIC90; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; BIOSYNTHESIS; CANDIDIASIS; CELL ADHESION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MULTIDRUG RESISTANCE; PATHOGENICITY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; BIOFILMS; CANDIDA; CANDIDA ALBICANS; CANDIDIASIS; CELL ADHESION; CELL DIVISION; DRUG RESISTANCE, MULTIPLE, FUNGAL; FLUCONAZOLE; GLUCANS; GLYCOSIDES; HUMANS; MICROBIAL SENSITIVITY TESTS; PEPTIDE HYDROLASES; PHOSPHOLIPASES; TRITERPENES; VIRULENCE FACTORS;

EID: 85018159712     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02396-16     Document Type: Article

References (54)

1. Centers for Disease Control and Prevention. 24 June 2016, posting date. Global emergence of invasive infections caused by the multidrugresistant yeast Candida auris. Centers for Disease Control and Prevention, Atlanta, GA. https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html. Accessed 1 July 2016.
2. Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. 2009. Candida auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal of an inpatient in a Japanese hospital. Microbiol Immunol 53:41-44. https://doi.org/10.1111/j.1348-0421.2008.00083.x.
3. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH. 2011. First three reported cases of nosocomial fungemia caused by Candida auris. J Clin Microbiol 49: 3139-3142. https://doi.org/10.1128/JCM.00319-11.
4. Chowdhary A, Sharma C, Duggal S, Agarwal K, Prakash A, Singh PK, Jain S, Kathuria S, Randhawa HS, Hagen F, Meis JF. 2013. New clonal strain of Candida auris, Delhi, India. Emerg Infect Dis 19:1670-1673. https://doi.org/10.3201/eid1910.130393.
5. Magobo RE, Corcoran C, Seetharam S, Govender NP. 2014. Candida auris-associated candidemia, South Africa. Emerg Infect Dis 20: 1250-1251. https://doi.org/10.3201/eid2007.131765.
6. Emara M, Ahmad S, Khan Z, Joseph L, Al-Obaid I, Purohit P, Bafna R. 2015. Candida auris candidemia in Kuwait, 2014. Emerg Infect Dis 21: 1091-1092. https://doi.org/10.3201/eid2106.150270.
7. Oh BJ, Shin JH, Kim M-N, Sung H, Lee K, Joo MY, Shin MG, Suh SP, Ryang DW. 2011. Biofilm formation and genotyping of Candida haemulonii, Candida pseudohaemulonii, and a proposed new species (Candida auris) isolates from Korea. Med Mycol 49:98-102. https://doi.org/10.3109/13693786.2010.493563.
8. Borman AM, Szekely A, Johnson EM. 2016. Comparative pathogenicity of United Kingdom isolates of the emerging pathogen Candida auris and other key pathogenic Candida species. mSphere 1:e00189-16. https://doi.org/10.1128/mSphere.00189-16.
9. Calvo B, Melo ASA, Perozo-Mena A, Hernandez M, Francisco EC, Hagen F, Meis JF, Colombo AL. 2016. First report of Candida auris in America: clinical and microbiological aspects of 18 episodes of candidemia. J Infect 73:369-374. https://doi.org/10.1016/j.jinf.2016.07.008.
10. Morales-Lopez SE, Parra-Giraldo CM, Ceballos-Garzon A, Martinez HP, Rodriguez GJ, Alvarez-Moreno CA, Rodriguez JY. 2017. Invasive infections with multidrug-resistant yeast Candida auris, Colombia. Emerg Infect Dis 23:162-164. https://doi.org/10.3201/eid2301.161497.
11. Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, Ryan L, Shackleton J, Trimlett R, Meis JF, Armstrong-James D, Fisher MC. 2016. First hospital outbreak of the globally emerging Candida auris in a European hospital. Antimicrob Resist Infect Control 5:35. https://doi.org/10.1186/s13756-016-0132-5.
12. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh R, Kerins J, Kemble SK, Pacilli M, Black SR, Landon E, Ridgway J, Palmore TN, Zelzany A, Adams EH, Quinn M, Chaturvedi S, Greenko J, Fernandez R, Southwick K, Furuya EY, Calfee DP, Hamula C, Patel G, Barrett P, Lafaro P, Berkow EL, Moulton-Meissner H, Noble-Wang J, Fagan RP, Jackson BR, Lockhart SR, Litvintseva AP, Chiller TM. 2017. Investigation of the first seven reported cases of Candida auris, a globally emerging invasive, multidrug-resistant fungus-United States, May 2013-August 2016. Am J Transplant 17: 296-299. https://doi.org/10.1111/ajt.14121.
13. Chowdhary A, Kumar VA, Sharma C, Prakash A, Agarwal K, Babu R, Dinesh KR, Karim S, Singh SK, Hagen F, Meis JF. 2014. Multidrug-resistant endemic clonal strain of Candida auris in India. Eur J Clin Microbiol Infect Dis 33:919-926. https://doi.org/10.1007/s10096-013-2027-1.
14. Khillan V, Rathore N, Kathuria S, Chowdhary A. 2014. A rare case of breakthrough fungal pericarditis due to fluconazole-resistant Candida auris in a patient with chronic liver disease, p 1-5. JMM Case Rep https://doi.org/10.1099/jmmcr.0.T00018.
15. Kim M-N, Shin JH, Sung H, Lee K, Kim E-C, Ryoo N, Lee J-S, Jung S-I, Park KH, Kee SJ, Kim SH, Shin MG, Suh SP, Ryang DW. 2009. Candida haemulonii and closely related species at 5 university hospitals in Korea: identification, antifungal susceptibility, and clinical features. Clin Infect Dis 48:e57-e61. https://doi.org/10.1086/597108.
16. Chakrabarti A, Sood P, Rudramurthy SM, Chen S, Kaur H, Capoor M, Chhina D, Rao R, Eshwara VK, Xess I, Kindo AJ, Umabala P, Savio J, Patel A, Ray U, Mohan S, Iyer R, Chander J, Arora A, Sardana R, Roy I, Appalaraju B, Sharma A, Shetty A, Khanna N, Marak R, Biswas S, Das S, Harish BN, Joshi S, Mendiratta D. 2015. Incidence, characteristics and outcome of ICU-acquired candidemia in India. Intensive Care Med 41: 285-295. https://doi.org/10.1007/s00134-014-3603-2.
17. Kumar D, Banerjee T, Pratap CB, Tilak R. 2015. Itraconazole-resistant Candida auris with phospholipase, proteinase and hemolysin activity from a case of vulvovaginitis. J Infect Dev Ctries 9:435-437. https://doi.org/10.3855/jidc.4582.
18. Ghannoum MA, Radwan SS. 1990. Candida adherence to epithelial cells, vol 1. CRC Press, Inc, Boca Raton, FL.
19. Chandra J, Mukherjee PK, Ghannoum MA. 2008. In vitro growth and analysis of Candida biofilms. Nat Protoc 3:1909-1924. https://doi.org/10.1038/nprot.2008.192.
20. Berman J, Sudbery PE. 2002. Candida albicans: a molecular revolution built on lessons from budding yeast. Nat Rev Genet 3:918-930.
21. Saville SP, Lazzell AL, Monteagudo C, Lopez-Ribot JL. 2003. Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2:1053-1060. https://doi.org/10.1128/EC.2.5.1053-1060.2003.
22. Moyes DL, Richardson JP, Naglik JR. 2015. Candida albicans-epithelial interactions and pathogenicity mechanisms: scratching the surface. Virulence 6:338-346. https://doi.org/10.1080/21505594.2015.1012981.
23. Ghannoum MA. 2000. Potential role of phospholipases in virulence and fungal pathogenesis. Clin Microbiol Rev 13:122-143. https://doi.org/10.1128/CMR.13.1.122-143.2000.
24. Fanning S, Mitchell AP. 2012. Fungal biofilms. PLoS Pathog 8:e1002585. https://doi.org/10.1371/journal.ppat.1002585.
25. Kuhn DM, Ghannoum MA. 2004. Candida biofilms: antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 5:186-197.
26. Price MF, Wilkerson ID, Gentry LO. 1982. Plate method for detection of phospholipase activity in Candida albicans. Sabouraudia 20:7-14. https://doi.org/10.1080/00362178285380031.
27. Shin JH, Kee SJ, Shin MG, Kim SH, Shin DH, Lee SK, Suh SP, Ryang DW. 2002. Biofilm production by isolates of Candida species recovered from nonneutropenic patients: comparison of bloodstream isolates with isolates from other sources. J Clin Microbiol 40:1244-1248. https://doi.org/10.1128/JCM.40.4.1244-1248.2002.
28. Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, Meis JF, Chowdharya A. 2015. Multidrug-resistant Candida auris misidentified as Candida haemulonii: characterization by matrix-assisted laser desorption ionization-time of flight mass spectrometry and DNA sequencing and its antifungal susceptibility profile variability by Vitek 2, CLSI broth microdilution, and Etest method. J Clin Microbiol 53:1823-1830. https://doi.org/10.1128/JCM.00367-15.
29. Jiménez-Ortigosa C, Paderu P, Motyl MR, Perlina DS. 2014. Enfumafungin derivative MK-3118 shows increased in vitro potency against clinical echinocandin-resistant Candida species and Aspergillus species isolates. Antimicrob Agents Chemother 58:1248-1251. https://doi.org/10.1128/AAC.02145-13.
30. Rueda C, Cuenca-Estrella M, Zaragoza O. 2014. Paradoxical growth of Candida albicans in the presence of caspofungin is associated with multiple cell wall rearrangements and decreased virulence. Antimicrob Agents Chemother 58:1071-1083.
31. Bizerra FC, Melo AS, Katchburian E, Freymuller E, Straus AH, Takahashi HK, Colombo AL. 2011. Changes in cell wall synthesis and ultrastructure during paradoxical growth effect of caspofungin on four different Candida species. Antimicrob Agents Chemother 55:302-310.
32. Abarenkov K, Henrik Nilsson R, Larsson KH, Alexander IJ, Eberhardt U, Erland S, Hoiland K, Kjoller R, Larsson E, Pennanen T, Sen R, Taylor AF, Tedersoo L, Ursing BM, Vralstad T, Liimatainen K, Peintner U, Koljalg U. 2010. The UNITE database for molecular identification of fungi-recent updates and future perspectives. New Phytol 186:281-285. https://doi.org/10.1111/j.1469-8137.2009.03160.x.
33. Odds FC. 1988. Candida and candidosis: a review and bibliography, 2nd ed, vol 1. Bailliere Tindall, London, England.
34. Hofs S, Mogavero S, Hube B. 2016. Interaction of Candida albicans with host cells: virulence factors, host defense, escape strategies, and the microbiota. J Microbiol 54:149-169. https://doi.org/10.1007/s12275-016-5514-0.
35. Tsui C, Kong EF, Jabra-Rizk MA. 2016. Pathogenesis of Candida albicans biofilm. Pathog Dis 74:ftw018. https://doi.org/10.1093/femspd/ftw018.
36. Kwon-Chung KJ, Bennett JE. 1992. Medical mycology. Lea & Febiger, Philadelphia, PA.
37. McGinnis MR. 1980. Laboratory handbook of medical mycology. Academic Press, New York, NY.
38. Larone DH. 1995. Medically important fungi: a guide to identification, 3rd ed. ASM Press, Washington, DC.
39. Ghannoum MA. 1998. Extracellular phospholipases as universal virulence factor in pathogenic fungi. Nihon Ishinkin Gakkai Zasshi 39:55-59. https://doi.org/10.3314/jjmm.39.55.
40. Cupp-Enyard C. 2009. Use of the protease fluorescent detection kit to determine protease activity. J Vis Exp 2009:1514. https://doi.org/10.3791/1514.
41. Daniels KJ, Srikantha T, Pujol C, Park YN, Soll DR. 2015. Role of Tec1 in the development, architecture, and integrity of sexual biofilms of Candida albicans. Eukaryot Cell 14:228-240. https://doi.org/10.1128/EC.00224-14.
42. Emerson RJ, IV, Camesano TA. 2004. Nanoscale investigation of pathogenic microbial adhesion to a biomaterial. Appl Environ Microbiol 70: 6012-6022. https://doi.org/10.1128/AEM.70.10.6012-6022.2004.
43. Fazly A, Jain C, Dehner AC, Issi L, Lilly EA, Ali A, Cao H, Fidel PL, Jr, Rao RP, Kaufman PD. 2013. Chemical screening identifies filastatin, a small molecule inhibitor of Candida albicans adhesion, morphogenesis, and pathogenesis. Proc Natl Acad Sci U S A 110:13594-13599. https://doi.org/10.1073/pnas.1305982110.
44. Hawser SP, Douglas LJ. 1994. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 62:915-921.
45. Holmes AR, van der Wielen P, Cannon RD, Ruske D, Dawes P. 2006. Candida albicans binds to saliva proteins selectively adsorbed to silicone. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:488-494. https://doi.org/10.1016/j.tripleo.2005.10.052.
46. Katragkou A, Chatzimoschou A, Simitsopoulou M, Georgiadou E, Roilides E. 2011. Additive antifungal activity of anidulafungin and human neutrophils against Candida parapsilosis biofilms. J Antimicrob Chemother 66:588-591. https://doi.org/10.1093/jac/dkq466.
47. Kuhn DM, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Comparison of biofilms formed by Candida albicans and Candida parapsilosis on bioprosthetic surfaces. Infect Immun 70:878-888. https://doi.org/10.1128/IAI.70.2.878-888.2002.
48. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob Agents Chemother 46:1773-1780. https://doi.org/10.1128/AAC.46.6.1773-1780.2002.
49. Rodger G, Taylor RL, Pearson GJ, Verran J. 2010. In vitro colonization of an experimental silicone by Candida albicans. J Biomed Mater Res B Appl Biomater 92:226-235. https://doi.org/10.1002/jbm.b.31509.
50. Zhao X, Daniels KJ, Oh SH, Green CB, Yeater KM, Soll DR, Hoyer LL. 2006. Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces. Microbiology 152:2287-2299. https://doi.org/10.1099/mic.0.28959-0.
51. Zhao X, Oh SH, Yeater KM, Hoyer LL. 2005. Analysis of the Candida albicans Als2p and Als4p adhesins suggests the potential for compensatory function within the Als family. Microbiology 151:1619-1630. https://doi.org/10.1099/mic.0.27763-0.
52. Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of yeasts, 3rd ed. Approved standard M27-A3. Clinical and Laboratory Standards Institute, Wayne, PA.
53. Canton E, Peman J, Viudes A, Quindos G, Gobernado M, Espinel-Ingroff A. 2003. Minimum fungicidal concentrations of amphotericin B for bloodstream Candida species. Diagn Microbiol Infect Dis 45:203-206. https://doi.org/10.1016/S0732-8893(02)00525-4.
54. Mukherjee PK, Chandra J, Retuerto M, Sikaroodi M, Brown RE, Jurevic R, Salata RA, Lederman MM, Gillevet PM, Ghannoum MA. 2014. Oral mycobiome analysis of HIV-infected patients: identification of Pichia as an antagonist of opportunistic fungi. PLoS Pathog 10:e1003996. https://doi.org/10.1371/journal.ppat.1003996.